T- and B-cell-mediated protection induced by novel, live attenuated pertussis vaccine in mice. Cross protection against parapertussis
Pascal Feunou Feunou, Julie Bertout, Camille Locht, Pascal Feunou Feunou, Julie Bertout, Camille Locht
Abstract
Background: Despite the extensive use of efficacious vaccines, pertussis still ranks among the major causes of childhood mortality worldwide. Two types of pertussis vaccines are currently available, whole-cell, and the more recent acellular vaccines. Because of reduced reactogenicity and comparable efficacy acellular vaccines progressively replace whole-cell vaccines. However, both types require repeated administrations for optimal efficacy. We have recently developed a live attenuated vaccine candidate, named BPZE1, able to protect infant mice after a single nasal administration.
Methodology/principal findings: We determined the protective mechanism of BPZE1-mediated immunity by using passive transfer of T cells and antibodies from BPZE1-immunized mice to SCID mice. Clearance of Bordetella pertussis from the lungs was mediated by both BPZE1-induced antibodies and CD4(+), but not by CD8(+) T cells. The protective CD4(+) T cells comprised IFN-gamma-producing and IL-17-producing subsets, indicating that BPZE1 induces both Th1 and Th17 CD4(+) T cells. In addition, and in contrast to acellular pertussis vaccines, BPZE1 also cross-protected against Bordetella parapertussis infection, but in this case only the transfer of CD4(+) T cells conferred protection. Serum from BPZE1-immunized mice was not able to kill B. parapertussis and did not protect SCID mice against B. parapertussis infection.
Conclusions/significance: The novel live attenuated pertussis vaccine BPZE1 protects in a pre-clinical mouse model against B. pertussis challenge by both BPZE1-induced antibodies and CD4(+) T cell responses. It also protects against B. parapertussis infection. However, in this case protection is only T cell mediated.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
References
- Greenberg DP, von König CH, Heininger U. Health burden of pertussis in infants and hildren. Pediatr Infect Dis J. 2005;24:S39–S43.
- McIntyre P, Wood N. Pertussis in early infancy: disease burden and preventive strategies. Curr Opin Infect Dis. 2009;22:215–223.
- Von König CH, Halperin S, Riffelmann M, Guiso N. Pertussis of adults and infants. Lancet Infect Dis. 2002;2:744–750.
- Crowcroft NS, Stein C, Duclos P, Birmingham M. How best to estimate the global burden of pertussis? Lancet Infect Dis. 2003;3:423–418.
- Edwards KM. Overview of pertussis: focus on epidemiology, sources of infection, and long term protection after infant vaccination. Pediatr Infect Dis J. 2005;24(Suppl.):S104–S108.
- Storsaeter J, Wolter J, Locht C. Pertussis vaccines. In Bordetella Molecular Microbiology. 2007. pp. 245–288. C Locht, editor Horizon Bioscience, Norfolk, UK.
- Jefferson T, Rudin M, DiPietrantonj C. Systematic review of the effects of pertussis vaccines in children. Vaccine. 2003;21:2003–2014.
- Sato Y, Kimura M, Fukumi H. Development of a pertussis component vaccine in Japan. Lancet. 1984;8369:122–126.
- Decker MD, Edwards KM. Acellular pertussis vaccines. Pediatr Clin North Am. 2000;47:309–335.
- Pichichero ME, Deloria MA, Rennels MB, Anderson EL, Edwards KM, et al. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a forth dose in 15- to 20-months-old children. Pediatrics. 1997;100:772–788.
- Olin P, Rasmussen F, Gustafsson L, Hallander HO, Heijbel H. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet. 1997;334:1569–1577.
- Hellwig SM, van Spriel AB, Schellekens JF, Mooi FR, van de Winkel JG. Immunoglobulin A-mediated protection against Bordetella pertussis infection. Infect Immun. 2001;69:4846–4850.
- Letowska I, Hryniewicz W. Epidemiology and characterization of Bordetella parapertussis strains isolated between 1995 and 2002 in and around Warsaw, Poland. Eur J Clin Microbiol Infect Dis. 2004;23:499–501.
- Parkhill J, Sebaihia M, Preston A, Murphy LD, Thomson N, et al. Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica. Nat Genet. 2003;35:32–40.
- Mastrantonio P, Giuliano M, Stefanelli P, Sofia T, De Marzi L, et al. Bordetella parapertussis infections. Dev Biol Stand. 1997;89:255–259.
- He Q, Viljanen MK, Arvilommi H, Aittanen B, Mertsola J. Whooping cough caused by Bordetella pertussis and Bordetella parapertussis in an immunized population. JAMA. 1998;280:635–637.
- Bergfors E, Trollfors B, Taranger J, Lagergard T, Sundh V, et al. Parapertussis and pertussis: differences and similarities in incidence, clinical course, and antibody responses. Int J Infect Dis. 1999;3:140–146.
- Heininger U, Stehr K, Schmitt-Grohe S, Lorenz C, Rost R, et al. Clinical characteristics of illness caused by Bordetella parapertussis compared with illness caused by Bordetella pertussis. Pediatr Infect Dis J. 1994;13:306–309.
- David S, van Furth R, Mooi FR. Efficacies of whole cell and acellular pertussis vaccines against Bordetella parapertussis in a mouse model. Vaccine. 2004;22:1892–1898.
- Wolfe DN, Goebel EM, Bjornstad ON, Restif O, Harvill ET. The O antigen enables Bordetella parapertussis to avoid Bordetella pertussis-induced immunity. Infect Immun. 2007;75:4972–4979.
- Mielcarek N, Debrie AS, Raze D, Bertout J, Rouanet C, et al. Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. PLoS Pathog. 2006;2:e65.
- Feunou PF, Ismaili J, Debrie AS, Huot L, Hot D, et al. Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1. Vaccine. 2008;26:5722–5727.
- Mills KH. Immunity to Bordetella pertussis. Microbes Infect. 2001;3:655–677.
- Mahon BP, Sheahan BJ, Griffin F, Murphy G, Mills KH. Atypical disease after Bordetella pertussis respiratory infection of mice with targeted disruptions of interferon-gamma receptor or immunoglobulin mu chain genes. J Exp Med. 1997;186:1843–1851.
- Centers for Disease Control and Prevention. Fatal case of unsuspected pertussis diagnosed from a blood culture-Minnesota, 2003. MMWR Morb Mortal Wkly Rep. 2004;53:131–132.
- Mills KH, Barnard A, Watkins J, Redhead K. Cell-mediated immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a murine respiratory infection model. Infect Immun. 1993;61:399–410.
- Byrne P, McGuirk P, Todryk S, Mills KH. Depletion of NK cells results in disseminating lethal infection with Bordetella pertussis associated with a reduction of antigen-specific Th1 and enhancement of Th2, but not Tr1 cells. Eur J Immunol. 2004;34:2579–2588.
- Kirimanjeswara GS, Mann PB, Harvill ET. Role of antibodies in immunity to Bordetella infections. Infect Immun. 2003;71:1719–1724.
- Leef M, Elkins KL, Barbic J, Shahin RD. Protective immunity to Bordetella pertussis requires both B cells and CD4 (+) T cells for key functions other than specific antibody production. J Exp Med. 2000;191:1841–1852.
- Menozzi FD, Mutombo R, Renauld G, Gantiez C, Hannah JH, et al. Heparin-inhibitable lectin activity of the filamentous hemagglutinin adhesin of Bordetella pertussis. Infect Immun. 1994;62:769–778.
- Higgins SC, Jarnicki AG, Lavelle ED, Mills KHG. TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells. J Immunol. 2006;177:7980–7989.
- Chen X, Howard OMZ, Oppenheim JJ. Pertussis toxin by inducing IL-6 promotes the generation of IL-17-producing CD4 cells. J Immunol. 2007;178:6123–6129.
- McGuirk P, McCann C, Mills KH. Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis. J Exp Med. 2002;195:221–231.
- Mills KHG, Ryan M, Ryan E, Mahon BP. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect Immun. 1998;66:594–602.
- Watanabe M, Nagai M. Whooping cough due to Bordetella parapertussis: an unresolved problem. Expert Rev Anti-infect Ther. 2004;2:447–454.
- Watanabe M, M Nagai. Reciprocal protective immunity against Bordetella pertussis and Bordetella parapertussis in a murine model of respiratory infection. Infect Immun. 2001;69:6981–6986.
- Goebel EM, Wolfe DN, Elder K, Stibitz S, Harvill ET. O antigen protects Bordetella parapertussis from complement. Infect Immun. 2008;76:1774–1780.
- Mascart F, Verscheure V, Malfroot A, Hainaut M, Piérard D, et al. Bordetella pertussis infection in 2-months-old infants promotes type 1 T cell responses. J Immunol. 2003;170:1504–1509.
- Woolard MD, Hensley LL, Kahula TH, Frelinger JA. Respiratory Francisella tularensis live vaccine strain infection induces Th17 cells and prostaglandin E2, which inhibits generation of gamma interferon-positive T cells. Infect Immun. 2008;76:2651–2659.
- Ma CS, Chew GYJ, Simpson N, Priyadarshi A, Wong M, et al. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J Exp Med. 2008;205:1551–1557.
- Page G, Sattler A, Kersten S, Thiel A, Radbruch A, et al. Plasma cell-like morphology of Th1-cytokine-producing cells associated with the of CD3 expression. Am J Path. 2004;164:409–417.
- Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-prodicing T cells. Immunity. 2006;24:179–189.
- Annunziato F, Cosmi L, Stantarlasci V, Maggi L, Liotta L, et al. Phenotypic and functional features of human Th17 cells. J Exp Med. 2007;204:1849–1861.
- Rowan AG, Fletcher JM, Ryan EJ, Moran B, Hegarty JE, et al. Hepatitis C virus-specific Th17 cells are suppressed by virus-induced TGF-beta. J Immunol. 2008;181:4485–4494.
- Nasso M, Fedele G, Spensieri F, Palazzo R, Costantino P, et al. Genetically detoxified pertussis toxin induces Th1/Th17 immune response through MAPKs and IL-10 dependent mechanisms. J Immunol. 2009;183:1892–1899.
- Fedele G, Nasso M, Stensieri F, Palazzo R, Frasca L, et al. Lipopolysaccharides from Bordetella pertussis and Bordetella parapertussis differently modulate human dendritic cell functions resulting in divergent prevalence of Th17-polarized responses. J Immunol. 2008;181:208–216.
- Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6:1123–1132.
- Dubin PJ, Kolls JK. Th17 cytokines and mucosal immunity. Immunol Rev. 2008;226:160–171.
- Locht C, Geoffroy MC, Renauld G. Common accessory genes for the Bordetella pertussis filamentous hemagglutinin and fimbrae share sequence similarities with the papC and papD gene families. EMBO J. 1992;11:3175–3183.
- Antoine R, Locht C. Roles of the disulfide bond and the carboxy-terminal region of the S1 subunit in the assembly and biosynthesis of pertussis toxin. Infect Immun. 1990;58:1518–1526.
- Sekura RD, Fish F, Manckark CR, Meade B, Zhang YL. Pertussis toxin. Affinity purification of a new ADP-ribosyltransferase. J Biol Chem. 1983;258:14647–14651.
- Menozzi FD, Gantiez C, Locht C. Interaction of Bordetella pertussis filamentous hemagglutinin with heparin. FEMS Microbiol Lett. 1991;78:59–64.
Source: PubMed